SCHEMBL5134552

SCHEMBL5134552

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(Cc1ccccc1)Cc1ccc(OC)cc1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
SMPD1 P17405 1/20 0.37
CRHR1 P34998 3/20 0.37
GAA P10253 2/20 0.36
CYP19A1 P11511 1/20 0.36
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALDH1A1 P00352 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
PPARD Q03181 1/20 0.36
BCHE P06276 1/20 0.36
PDE4B Q07343 1/20 0.36
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5071417 0.94 TSHR (0.39) TSHRSMPD1CRHR1GAACYP19A1
SCHEMBL5137583 0.92 HSP90AA1 (0.39) TSHRCRHR1GAAMAPT
SCHEMBL5134566 0.88 TSHR (0.41) TSHRALDH1A1KDM4EBCHEPDE4B
SCHEMBL5135337 0.88 TSHR (0.37) TSHRGAALMNAPPARDBCHE
SCHEMBL1912805 0.88 PTGES (0.37) TSHRTP53MAPTHTT
SCHEMBL648843 0.88 PTGES (0.37) TSHRTP53MAPTHTT
SCHEMBL648844 0.88 PTGES (0.37) TSHRTP53MAPTHTT
SCHEMBL5134768 0.87 TSHR (0.41) TSHRGAATP53MAPTSMN1; SMN2
SCHEMBL5135939 0.86 HSP90AA1 (0.38) TSHRCRHR1GAAMAPT
SCHEMBL5074803 0.85 MEN1 (0.36) TSHRGAATP53SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed